Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
Nephrons01:10

Nephrons

2.3K
The kidneys are intricate organs with millions of working units known as nephrons. Each nephron features two major structures: the renal corpuscle, which facilitates blood plasma filtration, and the renal tubule, which handles the glomerular filtrate. Blood supply is directly linked to the nephrons. The renal corpuscle consists of the glomerulus, a capillary network, and the Bowman's capsule, a double-walled epithelial structure that encases the glomerulus. The filtering of blood plasma...
2.3K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

A Core Outcome Set for Localized Renal Cell Cancer (L-RCC-COS).

European urology focus·2026
Same author

State of the nation: Understanding the current NHS treatment pathway to identify opportunities to advance future care of patients with high-risk non-muscle invasive bladder cancer in the UK (SPAN-UK).

BJUI compass·2026
Same author

Characteristics of Patients With Advanced or Metastatic Urothelial Cancer Unable to Complete Six Cycles Chemotherapy.

Cancer medicine·2026
Same author

Corrigendum to "Long-term real-world survival outcomes with dual immune checkpoint blockade in synchronous metastatic renal cell carcinoma: implications for the design of prospective cytoreductive nephrectomy trials" [Eur. Urol. Open Sci. 83 (2026) 133-141].

European urology open science·2026
Same author

Modern management of locally advanced renal cancers with inferior vena cava thrombus.

World journal of urology·2026
Same author

Think Twice Before You Continue Long-term FU in Localised nccRCC after Surgery.

European urology oncology·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Jun 20, 2025

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.6K

腎臓細胞がん

Matthew Young1, Francesca Jackson-Spence1, Luis Beltran2

  • 1Barts Cancer Institute, Queen Mary University of London, London, UK.

Lancet (London, England)
|July 21, 2024
PubMed
まとめ
この要約は機械生成です。

腎臓細胞がんの治療における最近の進歩は 局所的で進行した腎臓がんの生存率を向上させました ペムブロリズマブや 免疫チェックポイント阻害剤のような 新しい補助療法が 治療のパラダイムを変えています

さらに関連する動画

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.6K
Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

8.9K

関連する実験動画

Last Updated: Jun 20, 2025

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.6K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.6K
Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

8.9K

科学分野:

  • 腫瘍学
  • 泌尿器科

背景:

  • 腎臓細胞癌 (RCC) の治療は著しく進み,患者の生存率が改善されました.
  • ここ10年で 局所的および進行した腎臓がんの両方の治療において 顕著な進展が見られました

研究 の 目的:

  • RCCの流行病学,病理学,診断をレビューする.
  • 局所から転移したRCCの現在のエビデンスベースの管理戦略について議論する.
  • 腎臓がんにおけるバイオマーカーの必要性を強調する

主な方法:

  • 疫学データの見直し
  • 病理学的発見の分析
  • 現在の治療戦略と新興治療戦略のエビデンスの統合
  • 画期的な臨床試験の議論

主要な成果:

  • ペムブロリズマブを含む補助療法は生存効果を示しています.
  • 免疫チェックポイント阻害剤は 進行したRCCの標準治療法です
  • リスク評価モデルは,治療の選択のために転移性RCCを分層化するのに役立ちます.

結論:

  • 腎臓細胞がんの現在の管理戦略は,生存率の改善につながりました.
  • ペムブロリズマブは,RCCの補助療法における画期的な進歩です.
  • 継続的な研究とバイオマーカーの開発は パーソナライズされた腎臓がん治療に不可欠です